The management of alcoholic hepatitis: A prospective comparison of scoring systems

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 6, 2013, Pages 603-610

  Lafferty, H ^a   Stanley, A J ^a   Forrest, E H ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CORTICOSTEROID; PENTOXIFYLLINE;

ADULT; AGE BILIRUBIN INR AND CREATININE SCORE; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG RESPONSE; GLASGOW ALCOHOLIC HEPATITIS SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE;

EID: 84883050648     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12414     Document Type: Article

References (26)

1. Morgan MY,. The treatment of alcoholic hepatitis. Alcohol Alcohol 1996; 31: 117-34.
2. Maddrey WC, Boitnott JK, Bedine MS, et al,. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-9.
3. Carithers JRL, Herlong HF, Diehl AM, et al,. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989; 110: 685-90.
4. Kulkarni K, Tran T, Medrano M, et al,. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004; 38: 453-9.
5. Forrest EH, Evans CDJ, Stewart S, et al,. Analysis of factors related to mortality in alcoholic hepatitis and the derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-9.
6. Forrest EH, Morris AJ, Stewart S, et al,. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-6.
7. Dunn W, Jamil LH, Brown LS, et al,. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-8.
8. Srikureja W, Kyulo NL, Runyon BA, Hu K-Q,. MELD is a better prognostic model than the Child-Turcotte-Pugh score or Discriminant Function in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-6.
9. Sheth M, Riggs M, Patel T,. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2.
10. Verma S, Ajudia K, Mendler M, Redeker A,. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006; 51: 1637-43.
11. O'Shea RS, Dasarathy S, McCullough AJ, et al,. AASLD practice guideline: alcoholic liver disease. Hepatology 2010; 51: 307-28.
12. Dominguez M, Rincon D, Abraldes JG, et al,. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747-56.
13. Forrest EH, Fisher NC, Singhal S, et al,. Comparison of the Glasgow alcoholic hepatitis score and the ABIC score for the assessment of alcoholic hepatitis. Am J Gastroenterol 2010; 105: 701-2.
14. Sandahl TTD, Jepsen P, Ott P, et al,. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand J Gastroenterol 2011; 46: 1127-32.
15. Mathurin P, Abdelnour M, Ramond M-J, et al,. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-9.
16. Morris JM, Forrest EH,. Bilirubin response to corticosteroids in alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005; 17: 759-62.
17. Louvet A, Naveau S, Abdelnour M, et al,. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-54.
18. Mathurin P, O'Grady J, Carithers RL, et al,. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-60.
19. Lolekha PH, Sritong N,. Comparison of techniques for minimizing interference of bilirubin on serum creatinine determined by the kinetic Jaffe reaction. J Clin Lab Anal 1994; 8: 391-9.
20. Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) 2011. Eligibility Criteria [on line]. Available at: http://stopah.com/page7.htm. Accessed September 20, 2011.
21. EASL. EASL clinical practice guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420.
22. Akriviadis E, Botla R, Briggs W, et al,. Pentoxifylline improves short term survival in severe alcoholic hepatitis: a double blind placebo controlled trial. Gastroenterology 2000; 119: 1637-48.
23. Louvet A, Diaz E, Dharancy S, et al,. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48: 465-70.
24. Morris JM, Dickson S, Neilson M, et al,. Granulocytapheresis in the treatment of severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2010; 22: 457-60.
25. Boitard J, Louvet A, Bismuth B, et al,. Tolerance and efficacy of the MARS system in patients with severe alcoholic hepatitis non-responder to steroids: a pilot study. Hepatology 2007; 46: 327A.
26. Mathurin P, Moreno C, Samuel D, et al,. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-800.